TickerTalks
Browse all tickers →
TickerTalks›$IBRX
IBIBRX

ImmunityBio, Inc.

$IBRX·$8.6B·Biotechnology·Healthcare
$7.45-3.6%YTD+268.8%1Y+170.9%
Mentions · last 7 days
2026-07-10: 169 posts2026-07-11: 46 posts2026-07-12: 76 posts2026-07-13: 236 posts2026-07-14: 182 posts2026-07-15: 224 posts2026-07-16: 204 posts1,147+24%
Price updated 5h ago·X counts updated 4h ago
IBIBRX
$IBRXImmunityBio, Inc.
$7.45-3.62%1.1k posts+24%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IBRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-07-16

Catching its breath after a run — could pick back up or fade from here.

Bladder-cancer immunotherapy story up 183% in a year — heavy insider selling and squeeze fuel colliding.

ImmunityBio makes ANKTIVA (a cytokine-based bladder cancer immunotherapy) — a real, FDA-approved product in the non-muscle-invasive bladder cancer market. The stock is up 183% over the past year on commercial launch traction, and now sits with heavy short interest, insider selling, and an approaching Q2 print.

  • Revenue grew 168% YoY last quarter (off a small base) — the ANKTIVA launch is scaling, and the sell-side is now modeling ~$49M in Q2 revenue with a realistic beat path.
  • Trades at 51x TTM sales — expensive multiple, but for a recently-approved oncology drug still in the first year of commercial expansion, the growth trajectory can justify it if it holds.
  • Two directors sold $2.7M combined on July 6 (Cheryl Cohen and Christobel Selecky, both with option-exempt exercises) — real distribution from board members near the price highs, and the pattern of director selling is worth naming.
  • 135M shares short with ~50%+ daily short volume — the squeeze setup is real, but so is the underlying bear thesis; short interest at this scale usually reflects specific concerns rather than just crowded positioning.
  • The July 2026 WHO Cancer Report calling for private-sector collaboration in LMICs is a real institutional tailwind for founder/CEO Patrick Soon-Shiong's global-access narrative — the kind of validation that helps the bull thesis persist through commercial-execution volatility.

Q2 earnings next week is the pivotal moment: revenue at or above $49M plus a Q3 guide reflecting continued ANKTIVA prescription growth is what restarts the run; a soft print with continued director selling is where the -8% recent biotech-rout momentum accelerates. Real oncology franchise, real squeeze mechanics, real short thesis — the setup is genuinely two-sided ahead of the print.

Agrees with X sentimentThe bullish X read on ANKTIVA traction, the WHO Cancer Report tailwind, and the squeeze setup is analytically fair — 135M shares short with 50%+ daily short volume is real fuel. Where the crowd's dismissal of the Selecky sale is too casual: two director sales on the same day near the highs deserves being named, not filtered out.

What to watch: Q2 earnings next week — need revenue at or above $49M and continued ANKTIVA prescription growth. A soft print with more director selling is where the biotech-rout momentum accelerates.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment⚠44 posts analyzed · as of 2026-07-15 · top-engagement diverged

ImmunityBio chatter reads bullish on catalyst-window optimism into July. Bulls emphasize ANKTIVA's traction in non-muscle-invasive bladder cancer, a July 2026 WHO Cancer Report calling for private-sector collaboration in LMICs (framed as a Dr. Patrick Soon-Shiong tailwind), Q2 revenue expectations around $49M with a realistic beat path, and ~50%+ daily short volume with 135M shares short setting up squeeze fuel. Institutions Strategic Investment Solutions +2,375% stake and Mayflower nearly doubled position are cited as smart-money accumulation. Bears point to a heavy CFO-adjacent sale by Christobel Selecky and continued short-seller pressure. Earnings expected next Mon-Tue.

Read the AI verdict + X sentiment for $IBRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IBRX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $IBRX

Direct beneficiary — Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines; the business model is a direct conduit for the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-185%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
93.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.62$-0.08-675.0%
Q4 2025Feb 23, 2026$-0.06$-0.08+25.0%
Q3 2025Nov 4, 2025$-0.07$-0.10+30.0%
Q2 2025Aug 5, 2025$-0.10$-0.100.0%
Next earningsTue, Aug 4·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$44.2M+167.6%99.5%-158%$-0.62$-77.1M
Q4 FY25$38.3M+407.0%88.9%-169%$-0.06$-71.2M
Q3 FY25$32.1M+425.1%87.1%-174%$-0.07$-69.7M
Q2 FY25$26.4M+2423.9%99.5%-270%$-0.10$-80.8M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$222.3M$195.9M – $248.8M-$0.85-$0.88 – -$0.812
FY27$452.0M$246.2M – $657.9M-$0.16-$0.38 – $0.072
FY28$1.4B$953.9M – $2.0B$0.54$0.31 – $0.841
FY29$2.3B$1.6B – $3.3B$0.95$0.55 – $1.471
FY30$3.1B$2.1B – $4.4B$1.41$0.82 – $2.181

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.52%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+31.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 113.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.085-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Cheryl CohenDirector131.2K sh$1.2MSellJul 1Christobel SeleckyDirector159.5K sh$1.4MSellJun 30Christobel SeleckyDirector1.0K sh$9KSellJun 29Christobel SeleckyDirector95.7K sh$862KSellJun 24Barry J. SimonDirector25.0K sh$197KSellJun 4Barry J. SimonDirector23.0K sh$165KSellFeb 24Barry J. SimonDirector75.0K sh$901KSellFeb 23Christobel SeleckyDirector25.0K sh$250KSellFeb 23Barry J. SimonDirector165.0K sh$1.7MSellFeb 20Barry J. SimonDirector10.0K sh$93K
1–10 of 12
+ 31 other (15 exempts · 9 inkinds · 6 awards · 1 conversion) in window

See when $IBRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

ImmunityBio, Inc. held its 2026 Annual Meeting on June 9, 2026, with approximately 85% of outstanding shares represented. Stockholders re-elected all nine incumbent directors (including founder/CEO Patrick Soon-Shiong) and ratified Deloitte & Touche LLP as auditor for fiscal 2026. Routine governance for a founder-controlled company; high participation rate reflects institutional engagement.

8-KMaterial agreementMay 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

ImmunityBio, Inc. (IBRX) entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) on May 14, 2026 for JBL to exclusively manufacture and supply the Tokyo-172 BCG strain for ImmunityBio's use in the U.S. and territories. ImmunityBio bears all development, clinical, and regulatory responsibilities for a 10-year initial term from FDA approval; no payments to JBL are due until approval, with at least 2 batches per year required post-approval. This agreement secures ImmunityBio's critical BCG supply chain ahead of anticipated commercial launch — a potentially material commercial enabler contingent on FDA approval.

8-KPress release / Reg FDApr 68-K — Item 7.01: Press release / Reg FD
AI summary

IBRX filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-06. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KMaterial agreementMar 318-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

IBRX entered into a amendment (8-K Item 1.01, dated 2026-03-31). Size: approximately $75.0 million. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

SC 13D/AActivist amendmentFeb 25SC 13D/A
8-KMaterial agreementJan 268-K — Item 1.01: Material agreement
+ 9 other (3 earnings 8-Ks · 2 proxys · 1 10-Q · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Nowbenzinga.com·4d agoModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout247wallst.com·7d agoImmunityBio: A Long-Term Bull Case Worth Watchingseekingalpha.com·10d agoImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?zacks.com·18d agoImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026gurufocus.com·46d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport